Senate Bill 21

Actions | Amendments
Last Action signed by Governor (Acts, ch. 65)
Title AN ACT relating to use of experimental treatments for terminal illnesses.
Bill Documents Current/Final
Introduced
Bill Request Number 193
Sponsors C. Embry Jr., J. Adams, M. Wilson
Summary of Original Version Create new sections of KRS Chapter 217 to define terms; permit eligible patients to use investigational drugs, biological products, or devices for a terminal illness; establish the conditions for use of such experimental treatments; prohibit sanctions of health care providers; clarify the duties of health care insurers regarding experimental treatments; prohibit certain actions by state officials.
Index Headings of Original Version Diseases - Investigational drugs, biological products, or devices, use by terminal patients
Drugs and Medicines - Investigational drugs, biological products, or devices, use by terminal patients
Health and Medical Services - Terminal patients, investigational drugs, biological products, or devices
Nurses - Investigational drugs, bioloical products, or devices, use by terminal patients
Pharmacists - Investigational drugs, biological products, or devices, use by terminal patients
Physicians and Practitioners - Investigational drugs, biological products, or devices, use by terminal patients
Public Health - Investigational drugs, biological products, or devices, use by terminal patients
Proposed Amendments Senate Committee Substitute 1
Votes Vote History

Actions

Top | Amendments
01/03/17
  • introduced in Senate
01/07/17
  • to Health & Welfare (S)
02/15/17
  • reported favorably, 1st reading, to Calendar with Committee Substitute
02/16/17
  • 2nd reading, to Rules
02/17/17
  • posted for passage in the Regular Orders of the Day for Tuesday, February 21, 2017
02/21/17
  • 3rd reading, passed 38-0 with Committee Substitute
02/22/17
  • received in House
02/27/17
  • to Health and Family Services (H)
03/01/17
  • posted in committee
03/02/17
  • reported favorably, 1st reading, to Calendar
03/03/17
  • 2nd reading, to Rules
03/06/17
  • posted for passage in the Regular Orders of the Day for Tuesday, March 7, 2017
03/14/17
  • 3rd reading, passed 87-7
  • received in Senate
  • enrolled, signed by President of the Senate
  • enrolled, signed by Speaker of the House
  • delivered to Governor
03/21/17
  • signed by Governor (Acts, ch. 65)

Proposed Amendments

Top | Actions
Amendment Senate Committee Substitute 1
Summary Retain original provisions; remove language relating to informed consent in hospice care settings.
Index Headings Diseases - Investigational drugs, biological products, or devices, use by terminal patients
Drugs and Medicines - Investigational drugs, biological products, or devices, use by terminal patients
Health and Medical Services - Terminal patients, investigational drugs, biological products, or devices
Nurses - Investigational drugs, bioloical products, or devices, use by terminal patients
Pharmacists - Investigational drugs, biological products, or devices, use by terminal patients
Physicians and Practitioners - Investigational drugs, biological products, or devices, use by terminal patients
Public Health - Investigational drugs, biological products, or devices, use by terminal patients

Last updated: 1/16/2019 3:02 PM (EST)